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ABSTRACT Vitamin K–dependent proteins, including matrix Gla-protein, have been shown to inhibit vascular
calcification. Activation of these proteins via carboxylation depends on the availability of vitamin K. We examined
whether dietary intake of phylloquinone (vitamin K-1) and menaquinone (vitamin K-2) were related to aortic
calcification and coronary heart disease (CHD) in the population-based Rotterdam Study. The analysis included
4807 subjects with dietary data and no history of myocardial infarction at baseline (1990–1993) who were followed
until January 1, 2000. The risk of incident CHD, all-cause mortality, and aortic atherosclerosis was studied in tertiles
of energy-adjusted vitamin K intake after adjustment for age, gender, BMI, smoking, diabetes, education, and
dietary factors. The relative risk (RR) of CHD mortality was reduced in the mid and upper tertiles of dietary
menaquinone compared to the lower tertile [RR  0.73 (95% CI: 0.45, 1.17) and 0.43 (0.24, 0.77), respectively].
Intake of menaquinone was also inversely related to all-cause mortality [RR  0.91 (0.75, 1.09) and 0.74 (0.59,
0.92), respectively] and severe aortic calcification [odds ratio of 0.71 (0.50, 1.00) and 0.48 (0.32, 0.71), respectively].
Phylloquinone intake was not related to any of the outcomes. These findings suggest that an adequate intake of
menaquinone could be important for CHD prevention. J. Nutr. 134: 3100–3105, 2004.
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Vitamin K is an essential cofactor for the conversion of
glutamate into -carboxyglutamate (carboxylation) and plays
an important role in hemostasis through the activation of
blood coagulation and anticoagulation factors in the liver
(1–3). Vitamin K–dependent proteins, however, are also
present in extrahepatic tissues such as bone and vascular tissue
(3–8). Matrix Gla-protein (MGP)3 was identified in human
atherosclerotic plaque, where it may prevent calcium precip-
itation similarly as it does in bone. This was clearly demon-
strated in MGP-knockout mice that die from massive aortic
and coronary calcification shortly after birth (9).
In healthy individuals dietary intake of vitamin K fills
the needs for coagulation, but little is known about vitamin
K requirements for extrahepatic processes (1,4). Carboxy-
lation of vitamin K– dependent proteins conveys the ability
to bind calcium ions, which is essential for their biological
activity (1). Elevated levels of undercarboxylated osteocal-
cin, a vitamin K– dependent protein involved in bone me-
tabolism, may result from subclinical vitamin K deficiency
and are frequently observed in the elderly (7). We hypoth-
esize that an inadequate dietary intake of vitamin K may
similarly result in undercarboxylation of vascular MGP,
leading to enhanced calcification of atherosclerotic lesions
and, consequently, an increased risk of coronary heart dis-
ease. Vitamin K is obtained from the diet as phylloquinone
(vitamin K-1) and menaquinone (MK-n, vitamin K-2).
Phylloquinone is abundant in dark-green leafy vegetables
and vegetable oils. The main dietary sources for menaqui-
none in Western populations are meats (MK-4) and fer-
mented foods, especially cheese and curds (mainly MK-8
and MK-9) (8,10).
We examined the association of dietary intake of phyllo-
quinone and menaquinone with the incidence of coronary
heart disease (CHD), all-cause mortality, and aortic calcifica-
tion in the population-based Rotterdam Study.
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METHODS
The Rotterdam Study. The Rotterdam Study is a prospective,
population-based study to assess the occurrence of diseases of the
elderly and to clarify their determinants (11). The cohort comprises
7983 men and women aged 55 y and over (78% of the eligible
population) who live in a defined district of Rotterdam. From August
1990 until June 1993, trained research assistants collected data on
current health, use of medication, medical history, lifestyle, and risk
indicators for chronic diseases during an extensive home interview.
The participants subsequently visited the study center for clinical
examination and assessment of diet.
Assessment of diet and vitamin K intake. The participants
indicated on a checklist all foods and beverages that they consumed
more than once a month during the preceding year. The completed
checklist formed the basis for an interview at the study center by a
trained dietician. A validated, semiquantitative food-frequency ques-
tionnaire was used (12). Intake of total energy, alcohol, macronutri-
ents, and a large number of micronutrients was computed using Dutch
food composition tables (13).
Concentrations of phylloquinone and menaquinone (MK-4
through MK-10) in a large series of Dutch foods were assessed at the
laboratory of one of the authors (C.V., Cardiovascular Research
Institute Maastricht, University of Maastricht), as described previ-
ously (10,14). Briefly, food items were supplemented with internal
standard (2,3-dihydrophylloquinone) and homogenized in water/
propanol-2 (1:2, v:v). The homogenates were extracted with hexane,
prepurified on Silica Sep-pak cartridges (Millipore), and analyzed by
HPLC using an Econosphere C-18 reversed phase column (Alltech)
with fluorescence detection after postcolumn electrochemical reduc-
tion. Isocratic elution was performed using a mixture of methanol-
isopropanol-water-tetramethylammonium octahydrotriborate (88.5:
10:1.5:0.045 by volume). The effluent of the column was reduced
with a Coulochem 5010 analytical cell (Environmental Sciences
Associates) maintained at a potential of 1.5 V and analyzed with a
Jasco 821-FP spectrofluorometric detector (Separations Analytical
Instruments). The excitation wavelength was 246 nm and the emis-
sion wavelength was 430 nm. Because of the long retention times for
the long-chain menaquinones (MK-7 through MK-10) the flow was
increased from 0.5 to 1.0 mL/min at 11 min after injection. Phyllo-
quinone and menaquinones were recorded in the same run. Authen-
tic menaquinones (Hoffmann-La Roche) served as reference materi-
als.
For some foods, we also used published data by others to update
our dietary database for vitamin K (3,8,15–18). Main dietary sources
of phylloquinone in our study were green leafy vegetables and vege-
table oils. Menaquinone was present in meats and eggs (MK-4 only),
fish, sauerkraut, cheese, and other dairy produce (MK-5 through
MK-10) (19).
Clinical examination. Height and weight were measured with
the subject wearing indoor clothing without shoes. BMI was com-
puted as weight (kg) divided by height squared (m). Sitting systolic
and diastolic blood pressure were measured twice with a random-zero
sphygmomanometer by a trained research assistant after a 5-min rest,
and values were averaged. A standard electrocardiogram was ob-
tained, which was interpreted by the Modular ECG Analysis System
(20). Diabetes mellitus was considered present when the subject
reported use of antidiabetes medication or insulin. Serum total cho-
lesterol level (mmol/L) was determined by an automated enzymatic
procedure (21). HDL cholesterol was measured similarly after precip-
itation of the non-HDL fraction.
Follow-up procedures. The present analysis is based on follow-
up data collected from baseline (1990–1993) until January 1, 2000.
Informed consent for collection of follow-up data was obtained from
7802 participants (98%). Information on vital status was obtained at
regular intervals from the municipal population registry. Fatal and
nonfatal events were reported by general practitioners (GPs) in the
research area (covering 85% of the cohort) by means of a comput-
erized system. Information from GPs outside the research area was
obtained by paper forms. In the Netherlands, the GP forms the link
to all specialized medical care and it is therefore unlikely that clinical
events are missed by our follow-up procedure. Research physicians
verified information using GP records and hospital discharge letters.
Events were coded independently by 2 physicians according to the
International Statistical Classification of Diseases and Related Health
Problems, 10th revision (ICD-10) (22). If there was disagreement,
consensus was reached in a separate session. Coded events were
reviewed by a medical expert in the field. The judgment by the expert
was considered definite in case of discrepancy.
In the present study, we examined risk of nonfatal myocardial
infarction (MI, ICD-10 code I21), CHD (I20–I25 and I46), and
overall mortality during follow-up. If reinfarctions occurred during
follow-up, only the first event was included in the analysis. Events
were considered fatal if death occurred within 28 d after the onset of
symptoms.
Assessment of aortic calcification. At baseline, a lateral radio-
graphic film of the lumbar spine was made from a fixed distance while
the participant was seated. Calcification was diagnosed off-line by
detecting calcified deposits in the abdominal aorta parallel and an-
terior to the lumbar spine (L1–L4), as described in more detail
elsewhere (23). The extent of abdominal aortic atherosclerosis was
scored on a scale of 0 to 5, according to the length of the involved
area. For the present analysis, the severity of aortic calcification was
graded as “absent or mild” (1 cm calcification), “moderate” (1 and
5 cm), or “severe” (5 cm).
Study population. Noninstitutionalized subjects who visited the
study center at baseline (n  6521, 82% of the cohort) were eligible
for a dietary interview. Diet was not assessed in 271 subjects who
participated in the pilot phase of the Rotterdam Study. Also, dietary
data were not obtained in 122 subjects suspected of dementia because
of expected difficulties in dietary recall and in a random group of 481
subjects due to logistic reasons. Furthermore, 212 dietary reports were
considered unreliable by the dietician and therefore excluded. Dietary
data were thus available for 5435 subjects. We excluded 613 subjects
with a history of MI, as diagnosed on the baseline electrocardiogram
(ECG), leaving 4807 subjects for the present analysis. Within this
cohort, 4683 subjects had baseline radiographic films for the assess-
ment of calcification in the abdominal aorta. The X-ray of 210
subjects did not allow proper scoring, leaving 4473 subjects for the
analysis of aortic calcification.
Statistical methods. Data analyses were performed using SPSS
11.0.1 for Windows. Two-sided P values  0.05 were considered
statistically significant. Descriptive data are presented as means SD
or, for categorical variables, as percentages. All statistical analyses
were performed for phylloquinone and menaquinone separately. Vi-
tamin K intakes were first adjusted for total energy intake and divided
into tertiles on the basis of the total cohort with dietary data. Pearson
correlations (r) for the association of vitamin K intake with lifestyle
factors and nutrient intakes were computed to identify potential
confounders.
The risk of coronary events and all-cause mortality in tertiles of
vitamin K intake was studied in a Cox regression model with adjust-
ment for age, gender, and total energy intake (model 1), using the
lower tertile as the reference. Survival time was calculated as the
number of days from entry into the study until death, occurrence of
nonfatal MI (in analyses of MI only), or January 1, 2000, whichever
occurred first. Hazard ratios, subsequently referred to RR, are pre-
sented with 95% CI and P for linear trend across the median values
of vitamin K tertiles.
The association between tertiles of vitamin K intake and aortic
calcification was studied in a multivariate logistic regression model
with adjustment for age, gender, and total energy intake (model 1).
Odds ratios (OR) are presented with 95% CI and P for trend.
Associations with moderate calcification (i.e., length of calcified area
1 cm and 5 cm) and severe calcification (5 cm) were examined
separately. In both analyses, the control group comprised subjects
with no or mild calcification (calcified area  1 cm).
All analyses were repeated with additional adjustment for BMI
(kg/m2), diabetes mellitus (i.e., treatment with oral antidiabetes med-
ication or insulin), smoking status (current, past, or never), pack-
years of cigarette smoking, education (3 categories), and intake of
alcohol (g/d), calcium (g/d), flavonols (total of quercetin, kaempferol,
and myricetin; mg/d), SFA (g/d), and PUFA (g/d) (model 2). In an
additional analysis, further adjustment was made for intake of vitamin
E (mg/d), vitamin C (mg/d), -carotene (mg/d), and fiber (g/d).
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The associations of vitamin K intake with serum total and HDL
cholesterol and systolic and diastolic blood pressure were obtained by
multiple linear regression analysis with adjustment for age, gender,
and other confounders as indicated above. The analysis of serum
cholesterol comprised 4581 subjects who were not treated with lipid-
reducing agents, and the analysis of blood pressure comprised 3370
subjects who were not treated with antihypertensive drugs.
We investigated whether serum HDL or total cholesterol could
mediate the effect of dietary vitamin K on coronary events, all-cause
mortality, or aortic calcification by adding these parameters to the
multivariate models and examining changes in risk estimates.
RESULTS
Characteristics of the study population are shown in Table
1. Men had higher intakes of vitamin K than women, but the
associations were reversed after adjustment for total energy
intake (253.5 vs. 241.1 g/d for phylloquinone and 29.2 vs.
26.9 g/d for menaquinone, respectively). All further associ-
ations were adjusted for total energy intake. Phylloquinone
intake was not correlated with menaquinone intake (r
 0.02). Phylloquinone intake was positively associated
with dietary fiber, calcium, vitamin antioxidants, flavonols,
and BMI and inversely associated with smoking (all P
 0.001). Menaquinone intake was positively associated with
intake of total fat and SFA, dietary calcium, BMI, and diabetes
mellitus and inversely associated with intake of PUFA (all P
 0.001). Additional adjustment for age and gender did not
change these associations.
In 4581 subjects not treated with lipid-reducing agents,
positive associations of phylloquinone intake with serum total
cholesterol (0.044 mmol  L1  100 g1, P  0.003) and
serum HDL (0.016 mmol  L1  100 g1, P  0.001) were
found. Menaquinone intake was inversely associated with se-
rum total cholesterol (0.025 mmol  L1  10 g1, P
 0.055), and positively associated with serum HDL (0.015
mmol  L1  10 g1, P  0.001). Intakes of phylloquinone
and menaquinone were not associated with blood pressure.
Incidence of CHD and all-cause mortality. From baseline
until January 1, 2000, 144 first nonfatal MI and 99 fatal
coronary events (54 of which were fatal MI) occurred in this
cohort of 4807 older men and women. A total of 602 subjects
died from other causes during follow-up. The study had a mean
duration of follow-up of 7.2 y (SD 1.9) and comprised 34,645
person-years.
Energy-adjusted intake of phylloquinone was not associated
with risk of nonfatal MI, incident CHD (fatal and nonfatal
events combined), CHD mortality, and all-cause mortality
(Table 2). For menaquinone intake (Table 3) there was an
inverse relationship with nonfatal MI in the upper vs. lower
tertile after adjustment for confounders, but findings were not
statistically significant. Risk of incident CHD, however, was
strongly and significantly reduced in the upper tertile of mena-
quinone intake (RR  0.59), as were risk of CHD mortality
(RR  0.43) and all-cause mortality (RR  0.74). Additional
adjustment for intake of fiber, vitamin C, vitamin E, and
-carotene did not change these results.
RR for coronary events and all-cause mortality with phyl-
loquinone and menaquinone intake remained essentially the
same after inclusion of serum total cholesterol and HDL cho-
lesterol in the multivariate models.
Atherosclerosis. Aortic calcification was mild or absent in
2874 subjects (64.3%), moderate in 1359 subjects (30.4%),
and severe in 240 subjects (5.4%). Categories of aortic calci-
fication were about equally distributed in men and women.
Moderate aortic calcification at baseline was strongly and
positively associated with risk of CHD mortality after adjust-
ment for age and gender [RR  1.95 (95% CI: 1.23, 3.10)], as
was severe aortic calcification [RR  2.75 (1.39, 5.43)]. Sim-
ilar positive associations of aortic calcification with nonfatal
coronary events and overall mortality were observed during
follow-up.
Mean intake of phylloquinone intake was similar in cate-
gories of aortic calcification (249.2, 249.0, and 245.0 g/d for
mild, moderate, and severe stages, respectively), after adjust-
ment for age, gender, and total energy intake. Menaquinone
intake was lower in subjects with severe aortic calcification
(25.6 g/d) than in subjects with moderate or mild calcifica-
tion (28.6 and 28.8 g/d, respectively; P  0.001).
Intake of phylloquinone was not significantly associated
with moderate or severe aortic calcification after adjustment
for age and gender (model 1) or after further adjustment for
confounders. In fully adjusted analysis (model 2), ORs for
severe calcification were 0.86 (0.61, 1.22) and 1.03 (0.72,
1.48) in the mid and upper tertiles of phylloquinone, respec-
tively, compared to the lower tertile. Menaquinone intake
showed no significant association with moderate calcification
(Table 4). For severe calcification, however, a strong inverse
TABLE 1
Baseline characteristics of 4807 Dutch men and women aged
55 y and over with no history of MI1
Men (n  1836) Women (n  2971)
Age, y 66.9  7.4 67.7  8.0
BMI, kg/m2 25.7  2.9 26.6  4.0
Smoking status, %
Current 29.8 19.1
Former 61.5 28.8
Never 8.7 52.0
Alcohol use, % 88.1 74.4
Educational level,2 %
Low 23.3 41.1
Intermediate 57.1 52.1
High 19.7 6.8
Blood pressure,3 mm Hg
Systolic 138.5  21.9 138.7  22.2
Diastolic 74.8  11.4 73.1  11.0
Serum cholesterol level,4
mmol/L
Total 6.3  1.1 6.9  1.2
HDL 1.2  0.3 1.5  0.4
Diabetes mellitus,5 % 3.1 3.6
Dietary intake
Total energy, kJ/d 9459  2130 7494  1693
Total fat, g/d 92.7  28.6 73.0  23.5
SFA, g/d 36.3  12.4 29.1  10.5
PUFA, g/d 17.9  8.3 13.5  6.8
Fiber, g/d 18.0  5.3 16.1  5.6
Flavonols,6 mg/d 26.7  11.7 29.8  12.4
Calcium, g/d 1.15  0.4 1.10  0.4
Vitamin C, mg/d 115.1  50.7 124.1  55.6
Vitamin E, mg/d 15.3  6.6 12.8  5.6
-Carotene, mg/d 1.6  0.7 1.5  0.8
Phylloquinone, g/d 257.1  116.1 244.3  131.9
Menaquinone, g/d 30.8  18.0 27.0  15.1
MK-4 7.7  3.4 6.3  2.8
MK-5 through MK-10 23.1  16.3 20.7  13.8
1 Values are means  SD or percentages.
2 Low, primary education or less; intermediate, secondary general
or vocational education; high, higher vocational education, university.
3 Data on blood pressure were missing for 26 subjects.
4 Data on serum lipids were missing for 27 subjects.
5 Defined as treatment with oral antidiabetes medication or insulin.
6 Total of quercetin, myricetin, and kaempferol.
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relationship with menaquinone intake persisted after adjust-
ment for BMI, smoking, education, diabetes, and intake of
alcohol, PUFA, SFA, flavonols, and calcium (Table 4). Ad-
ditional adjustment for intake of fiber, vitamin C, vitamin E,
and -carotene did not change these results.
Interaction terms between gender and intake of phylloqui-
none or menaquinone were not significant in the multivariate
models (all P  0.15). Additional adjustment for serum total
cholesterol or HDL cholesterol did not change the associations
of dietary phylloquinone or menaquinone with aortic calcifi-
cation.
DISCUSSION
The results of this study suggest a protective effect of dietary
menaquinone intake against CHD in older men and women.
As indicated by the inverse association with all-cause mortal-
ity, high intake of menaquinone does not increase the risk for
other major diseases, such as cancer. There was no consistent
association of phylloquinone intake with CHD, mortality, or
aortic calcification.
In contrast to phylloquinone, intake of menaquinone
(mainly MK-4 from eggs and meat, and MK-8 and MK-9 from
cheese) (19) is not related to a healthy lifestyle or diet, which
makes it unlikely that the observed reduction in coronary risk
is due to confounding. Subjects with a history of MI were
excluded from the analysis to avoid bias that may arise from
intentional changes in diet. Intake of menaquinone was in-
versely associated with severe aortic calcification in asymp-
tomatic subjects, which provides additional support for a
causal relationship between menaquinone and CHD. Aortic
atherosclerosis was assessed during the baseline examination of
the Rotterdam Study by detection of calcified deposits in the
aorta on abdominal X-rays (23). The method shows good
agreement with coronary calcification scores obtained by elec-
tron beam tomography (24) and is predictive for cardiovascu-
lar mortality (25).
Vegetables and vegetable oils are the main dietary sources
for phylloquinone (8,17,19). The intake of phylloquinone of
around 250 g/d in our study is higher than in the U.S.
population aged 55 and over, where intakes are 80–210 g/d
(26). This may be explained by the relatively high consump-
tion of vegetables in the Netherlands, which was around 200
g/d in the Rotterdam Study. For menaquinone (MK-n), dietary
data are scanty in the literature. We therefore analyzed foods
and beverages frequently consumed in the Netherlands for
MK-4 through MK-10 and linked these data to the dietary
database of the Rotterdam Study (19). Intake of menaquinone
comprised 10% of the total vitamin K intake, but its bioavail-
ability is probably higher than for phylloquinone that is
strongly bound to vegetable fiber (14). Menaquinone in our
Dutch population was mainly derived from dairy products,
especially cheese (19). Interestingly, in this respect, cheese has
not been established as a dietary risk factor for cardiovascular
disease in epidemiological studies, despite its high levels of
saturated fat and salt. We hypothesize that menaquinones in
cheese (MK-8 and MK-9) could exert a beneficial effect in the
cardiovascular system and that the high cheese consumption
TABLE 2
Association of coronary events and all-cause mortality with intake of phylloquinone
in 4807 Dutch men and women aged 55 y and over1
Energy-adjusted phylloquinone intake (g/d)
P for trend200 200–278 278
n 1588 1608 1611
Median intake, g/d 154.6 236.5 336.9
Nonfatal MI
Person-years 11323 11556 11766
Events, n 48 56 40
RR, model 12 1 1.19 (0.81, 1.75) 0.86 (0.56, 1.30) 0.44
RR, model 23 1 1.14 (0.77, 1.70) 0.84 (0.54, 1.31) 0.42
Incident CHD4
Person-years 11323 11556 11766
Events, n 82 81 70
RR, model 1 1 1.01 (0.74, 1.38) 0.89 (0.64, 1.22) 0.45
RR, model 2 1 1.00 (0.73, 1.37) 0.89 (0.63, 1.25) 0.48
CHD mortality5
Person-years 11502 11764 11880
Events, n 36 30 33
RR, model 1 1 0.86 (0.53, 1.40) 0.98 (0.67, 1.57) 0.94
RR, model 2 1 0.90 (0.55, 1.48) 1.02 (0.61, 1.69) 0.93
All-cause mortality
Person-years 11502 11764 11880
Events, n 246 240 215
RR, model 1 1 0.98 (0.82, 1.17) 0.91 (0.75, 1.09) 0.28
RR, model 2 1 1.02 (0.85, 1.23) 0.94 (0.77, 1.14) 0.53
1 RR obtained by Cox proportional hazard analysis, with 95% CI in parentheses and P for linear trend across the tertiles.
2 Model includes age, gender, and total energy intake.
3 Model includes age, gender, total energy intake, BMI, smoking status, pack-years of cigarette smoking, diabetes, education (3 categories), and
intake of alcohol, SFA, PUFA, flavonols (quercetin, myricetin, and kaempferol), and calcium.
4 CHD comprises fatal and nonfatal MI, sudden cardiac death, and other forms of acute and chronic ischemic heart disease (ICD-10 codes I20–I25
and I46).
5 CHD events followed by death within 28 d after the onset of symptoms.
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in France and the Mediterranean countries may possibly ac-
count for lower prevalences of CHD. Menaquinone is also
produced by the intestinal flora, but the absorption seems to be
limited (27). In our study, however, it was not possible to
quantify endogenous menaquinone synthesis. Dietary intake of
menaquinone is reflected in serum levels. In healthy Japanese
subjects who consumed fermented soybean (natto) high in
menaquinone (especially MK-7), serum concentrations of
TABLE 3
Association of coronary events and all-cause mortality with intake of menaquinone
in 4807 Dutch men and women aged 55 y and over1
Energy-adjusted menaquinone intake (g/d)
P for trend21.6 21.6–32.7 32.7
n 1578 1605 1624
Median intake, g/d 15.1 26.9 40.9
Nonfatal MI
Person-years 11181 11549 11915
Events, n 51 57 36
RR, model 12 1 1.15 (0.79, 1.69) 0.74 (0.48, 1.14) 0.18
RR, model 23 1 1.08 (0.73, 1.62) 0.67 (0.41, 1.09) 0.12
Incident CHD4
Person-years 11323 11556 11766
Events, n 86 89 58
RR, model 1 1 1.05 (0.78, 1.42) 0.71 (0.51, 1.00) 0.048
RR, model 2 1 0.96 (0.70, 1.31) 0.59 (0.40, 0.86) 0.007
CHD mortality5
Person-years 11356 11747 12043
Events, n 41 35 23
RR, model 1 1 0.84 (0.54, 1.33) 0.59 (0.35, 0.99) 0.045
RR, model 2 1 0.73 (0.45, 1.17) 0.43 (0.24, 0.77) 0.005
All-cause mortality
Person-years 11356 11747 12043
Events, n 258 248 195
RR, model 1 1 0.97 (0.82, 1.16) 0.81 (0.67, 0.98) 0.030
RR, model 2 1 0.91 (0.75, 1.09) 0.74 (0.59, 0.92) 0.007
1 RR obtained by Cox proportional hazard analysis, with 95% CI in parentheses and P for linear trend across the tertiles.
2 Model includes age, gender, and total energy intake.
3 Model includes age, gender, total energy intake, BMI, smoking status, pack-years of cigarette smoking, diabetes, education (3 categories), and
intake of alcohol, SFA, PUFA, flavonols (quercetin, myricetin, and kaempferol), and calcium.
4 CHD comprises fatal and nonfatal MI, sudden cardiac death, and other forms of acute and chronic ischemic heart disease (ICD-10 codes I20–I25
and I46).
5 CHD events followed by death within 28 d after the onset of symptoms.
TABLE 4
Association of aortic calcification with intake of menaquinone in 4473 Dutch men and women aged 55 y and over1,2
Energy-adjusted menaquinone intake (g/d)
P for trend21.6 21.6–32.7 32.7
n 1468 1493 1512
Median intake, g/d 15.1 26.9 40.9
Moderate calcification
Controls, n 916 958 1000
Cases, n 454 452 453
OR, model 13 1 0.93 (0.79, 1.10) 0.94 (0.80, 1.11) 0.49
OR, model 24 1 0.91 (0.77, 1.09) 0.93 (0.76, 1.12) 0.45
Severe calcification
Controls, n 916 958 1000
Cases, n 98 83 59
OR, model 1 1 0.75 (0.54, 1.03) 0.56 (0.39, 0.80) 0.001
OR, model 2 1 0.71 (0.50, 1.00) 0.48 (0.32, 0.71) 0.001
1 Aortic calcification was graded according to the length of the calcified area, i.e., no/mild (reference), 1 cm; moderate, 1 and 5 cm; severe,
5 cm.
2 OR obtained by multivariate logistic regression, with 95% CI in parentheses and P for linear trend across the tertiles.
3 Model includes age, gender, and total energy intake.
4 Model includes age, gender, total energy intake, BMI, smoking status, pack-years of cigarette smoking, diabetes, education (3 categories), and
intake of alcohol, SFA, PUFA, flavonols (quercetin, myricetin, and kaempferol), and calcium.
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MK-7 and carboxylated osteocalcin were significantly in-
creased (28).
Vascular tissue and calcified plaques contain MGP, a vita-
min K–dependent protein known to prevent excessive cal-
cium deposition in bone (1–4,7,8). Lack of vascular MGP
resulted in excessive aortic and coronary calcification in
knockout mice (9). The inverse association of menaquinone
with aortic calcification and CHD in our study may be ex-
plained by undercarboxylation of vascular MGP and conse-
quently enhanced calcification of atherosclerotic lesions. Cal-
cified plaques are more prone to rupture, which will elicit a
thrombotic response, thereby increasing the risk of a coronary
event (29). Another vitamin K–dependent protein found in
the vessel wall is protein S (30). Together with activated
protein C, this anticoagulant plays an important role in pre-
venting clot formation at the inner surface of the vessel wall.
However, the quantitative contribution of extrahepatic pro-
tein S synthesis to hemostasis is probably small.
There is evidence for a differential effect of vitamin K
subtypes in the cardiovascular system. Rats at our laboratory
were fed diets containing phylloquinone, menaquinone, or
both after treatment with high doses of warfarin. Despite
similar in vitro cofactor activity for -carboxylase, menaqui-
none but not phylloquinone supplementation prevented war-
farin-induced arterial calcification (31). The tissue-specific use
of phylloquinone and menaquinone in rats was assessed by
measuring the ratios of quinone over epoxide (K:KO ratios)
during warfarin treatment. In the arterial vessel wall, K:KO
ratios were substantially lower for phylloquinone than for
menaquinone whereas the reverse was observed for the liver,
suggesting a tissue-specific utilization of vitamin K subtypes
(31). In a recent trial in humans, phylloquinone was almost
exclusively incorporated into the triacylglycerol-rich lipopro-
tein (TGRLP) fraction after intestinal absorption, whereas a
substantial part of the menaquinones was recovered from the
LDL fraction (32). The TGRLP fraction is mainly cleared by
the liver, whereas LDL forms a transport system to extrahe-
patic tissues. Menaquinone supplementation lowered serum
cholesterol levels in a study of 17 dialysis patients (33). In our
population of healthy older subjects, we confirmed the favor-
able effect of menaquinone on blood lipids but effects were
small and could not explain the inverse relation that we
observed between dietary menaquinone and CHD.
In conclusion, our findings suggest a protective effect of
menaquinone intake against CHD, which could be mediated
by inhibition of arterial calcification. Adequate intake of foods
rich in menaquinones, such as curds and (low-fat) cheese, may
contribute to CHD prevention.
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